hackint0sh/New-Dataset huggingface dataset:
Participants in this study will have already had blood tests as part of their usual care. Their previously collected health information and blood test results will be used to help train and test the AI algorithms. Participants will not undergo any new procedures for the study itself. conditions: Acute Coronary Syndrome conditions: Angina Pectoris conditions: NSTEMI - Non-ST Segment Elevation MI conditions: STEMI - ST Elevation Myocardial Infarction studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: PROSPECTIVE count: 2700 type: ESTIMATED measure: Training of AI models measure: Testing of AI models measure: Training of AI models measure: Testing of AI models: sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Landeskrankenhaus-Universitätsklinikum Graz status: RECRUITING city: Graz state: Styria / Steiermark zip: 8036 country: Austria name: Heiko Bugger, MD role: CONTACT phone: +43 316 385 30177 email: heiko.bugger@medunigraz.at lat: 47.06667 lon: 15.45 hasResults: False
nctId: NCT06384833 id: Rama briefTitle: Combination of Vitamin C and N-Acetylcysteine to Improve Functional Outcome After Rotator Cuff Repair overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2025-09-01 date: 2026-05-01 date: 2024-04-25 date: 2024-04-25 name: Mahidol University class: OTHER briefSummary: The goal of this clinical trial is to learn if vitamin C and N-acetylcysteine work to improve shoulder functional score after rotator cuff repair. It will also learn about the safety of vitamin C and N-acetylcysteine. The main questions it aims to answer are:
Take vitamin C and N-acetylcysteine or a placebo every day for 45 days. Visit the OPD three times at 2 week, 6 month and 12 month after surgery for checkups and tests. conditions: Rotator Cuff Tears studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: OUTCOMES_ASSESSOR count: 110 type: ESTIMATED name: Ascorbic acid name: N-acetyl cysteine name: placebo measure: ASES score measure: UCLA shoulder scale measure: WORC index measure: Tendon healing at 6 months postoperatively sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06384820 id: R3767-ONC-2330 id: 2023-510514-38-00 type: REGISTRY domain: EU CT Number briefTitle: Study of Cemiplimab Alone or in Combination With Fianlimab and/or Other Experimental Agents in Adult Participants With Peri-operative Stage III/IV Cutaneous Squamous Cell Carcinoma (CSCC) overallStatus: NOT_YET_RECRUITING date: 2024-11-14 date: 2026-06-08 date: 2030-05-06 date: 2024-04-25 date: 2024-04-25 name: Regeneron Pharmaceuticals class: INDUSTRY briefSummary: This study is researching an investigational drug called REGN2810, also known as cemiplimab, when combined with another investigational drug called REGN3767, also known as fianlimab (each individually called a "study drug" or called "study drugs" when combined). The study is focused on a type of skin cancer known as cutaneous squamous cell carcinoma (CSCC).
* Whether the body makes antibodies against the study drug(s) (which could make the drug(s) less effective or could lead to side effects) conditions: Cutaneous Squamous Cell Carcinoma studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 140 type: ESTIMATED name: cemiplimab name: fianlimab measure: Pathological complete response (pCR) rate by blinded independent pathological review (BIPR) measure: pCR rate by local pathological review measure: Major pathological response (MPR) measure: Event-free survival (EFS) measure: Disease free survival (DFS) measure: Objective response rate (ORR) prior to surgery measure: Overall survival (OS) measure: Occurrence of treatment-emergent adverse events (TEAEs) measure: Occurrence of immune-mediated adverse events (imAEs) measure: Occurrence of treatment-related TEAEs measure: Occurrence of adverse event of special interest (AESI) measure: Occurrence of treatment-emergent serious adverse events (SAEs) measure: Occurrence of laboratory abnormalities measure: Occurrence of death due to TEAE measure: Occurrence of interruption of study drug(s) due to TEAEs measure: Occurrence of discontinuation of study drug(s) due to TEAEs measure: Occurrence of cancellation of surgery due to TEAE measure: Occurrence of delay to surgery due to TEAE measure: Concentrations of cemiplimab in serum measure: Concentrations of fianlimab in serum measure: Concentrations of other experimental agents (as applicable) in serum measure: Incidence of anti-drug antibodies (ADA) to cemiplimab measure: Incidence of ADA to fianlimab measure: Incidence of ADA to other experimental agents (as applicable) measure: Titer of ADA to cemiplimab measure: Titer of ADA to fianlimab measure: Titer of ADA to other experimental agents (as applicable) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06384807 id: BHV1510-101 (PBI-410-101) briefTitle: A Phase 1/2 Study of PBI-410 in Advanced Solid Tumors overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2028-02 date: 2028-02 date: 2024-04-25 date: 2024-04-25 name: Pyramid Biosciences class: INDUSTRY briefSummary: This is a Phase 1/2, first in human (FIH), open-label, multicenter study of PBI-410 in participants with previously treated, advanced solid tumors. conditions: Solid Tumor studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NA interventionModel: SEQUENTIAL interventionModelDescription: Dose escalation followed by enrollment in signal-finding cohorts. primaryPurpose: TREATMENT masking: NONE count: 170 type: ESTIMATED name: PBI-410 measure: Phase 1: Number of patients with adverse events (AEs) measure: Phase 1: Recommended dose for expansion (RDE) and maximum tolerated dose (MTD) measure: Phase 2: Objective Response Rate (ORR) measure: Phase 2: Number of patients with AEs measure: Phase 2: Duration of Response (DoR) measure: Phase 1 and 2: Maximum Plasma Concentration (Cmax) of PBI-410 measure: Phase 1 and 2: Area Under the Concentration versus time Curve (AUClast) from the end of infusion to the last measurable concentration of PBI-410 measure: Phase 1 and 2: Area Under the Concentration versus time curve extrapolated to infinity (AUCinf) measure: Phase 1 and 2: Elimination half-life (t1/2) of PBI-410 in plasma measure: Phase 1: ORR measure: Phase 1: Duration of Response (DoR) measure: Phase 1 and 2: Immunogenicity of PBI-410 measure: Phase 2: Disease control rate (DCR) measure: Phase 2: Progression free survival (PFS) measure: Phase 2: Overall survival (OS) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06384781 id: 2130836 id: R61DA059892-01 type: NIH link: https://reporter.nih.gov/quickSearch/R61DA059892-01 briefTitle: Development, Refinement, and Validation of a Peer Support Specialist Checklist for Individuals With Opioid Use Disorder / STAMPS: South Carolina Buprenorphine Treatment Initiation, Adherence, and Retention Utilizing Mobile Health Units and Peer Support Specialists overallStatus: RECRUITING date: 2024-04 date: 2025-01 date: 2025-01 date: 2024-04-25 date: 2024-04-25 name: Prisma Health-Upstate class: OTHER name: Clemson University name: National Institute on Drug Abuse (NIDA) briefSummary: This study seeks to develop a tool to better guide and operationalize peer recovery coaching service delivery specifically for patients with opioid use disorder. This study will entail the initial development, acceptability, and validity of this tool in a sample of both peer support specialists (PSSs) and patients with opioid use disorder (OUD). This checklist will be adapted from ACE model PSS interventions for SUD broadly. Open-ended qualitative research questions regarding PSSs roles and responsibilities, patients' needs for recovery support, and perceptions of the checklist will be administered. Participants (PSSs and individuals with OUD) will also answer survey questions in which they indicate their satisfaction and likely to use the tool with the proposed services offered in the checklist. Outcome measures include satisfaction, perceived use of use, and perceived helpfulness of the checklist. We hypothesize that using both PSS and patient input will result in a validated intervention protocol with demonstrated acceptability using it with patients with OUD. conditions: Opioid Use Disorder studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: PROSPECTIVE count: 90 type: ESTIMATED measure: Phase 1: Conceptualization measure: Phase 2: Conceptulization measure: Phase 3: Refinement measure: Phase 4: Validation measure: Phase 5: Preliminary efficacy sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Prisma Addiction Medicine Center - Mobile Health Clinic status: RECRUITING city: Clinton state: South Carolina zip: 29325 country: United States name: Marisol A Miranda, BS role: CONTACT phone: 864-501-9693 email: marisol.miranda@prismahealth.org name: Kaileigh A Byrne, PhD role: PRINCIPAL_INVESTIGATOR lat: 34.47263 lon: -81.88066 facility: Prisma - Addiction Medicine Center Mobile Health Clinic status: RECRUITING city: Seneca state: South Carolina zip: 29672 country: United States name: Marisol A Miranda, BS role: CONTACT phone: 864-501-9693 email: marisol.miranda@prismahealth.org name: Kaileigh A Byrne, PhD role: PRINCIPAL_INVESTIGATOR lat: 34.68566 lon: -82.9532 hasResults: False
nctId: NCT06384768 id: EBIst id: 1919B012104428 type: OTHER_GRANT domain: TUBITAK briefTitle: Video Training on Pre-Pregnancy Fear of Birth in Male Partners overallStatus: COMPLETED date: 2022-02-01 date: 2022-05-01 date: 2022-08-30 date: 2024-04-25 date: 2024-04-26 name: Istanbul University - Cerrahpasa (IUC) class: OTHER briefSummary: This study aimed to evaluate the effect of an online video training on fears surrounding childbirth given to male partners before the pregnancy of their spouses. The study conducted with 43 male (22 intervention; 21 control) participants. Participants were divided into intervention and control groups. The intervention group was given video training on pregnancy and the birth process. \"Descriptive Information Form\" and the "Male-Childbirth Fear Prior to Pregnancy Scale" was used for data collection. Before the intervention, it was found that the fear level of childbirth was low. The video training given to male partners before the pregnancy of their spouses diminished the fear of birth but did not create a significant difference. These findings support long-term training that includes video tutorials for parents before birth. Interactive, participatory birth preparation training is likely to enhance the training's appeal for male partners. conditions: Fear of Childbirth studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 43 type: ACTUAL name: Video training measure: Fear of Childbirth sex: MALE stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Istinye University city: Istanbul country: Turkey lat: 41.01384 lon: 28.94966 hasResults: False
nctId: NCT06384755 id: 645788 id: 2022_HE2_409659 type: OTHER_GRANT domain: The Dam Foundation id: 645788 type: OTHER domain: Regional Ethics Committee (REK), South-East Norway briefTitle: Honest Open Proud for Psychotic and Bipolar Disorder in Norway acronym: HOP-NOR overallStatus: RECRUITING date: 2024-04-20 date: 2024-12-31 date: 2026-12-31 date: 2024-04-25 date: 2024-04-25 name: Oslo University Hospital class: OTHER name: University of Oslo briefSummary: The purpose of this pilot study is to evaluate the feasibility, acceptability and efficacy of a Norwegian adaptation of the group-based intervention 'Honest Open Proud' among adults with psychotic and bipolar disorders in an outpatient setting. conditions: Psychotic Disorders conditions: Bipolar Disorder conditions: Disclosure studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 40 type: ESTIMATED name: Honest Open Proud program measure: Stigma Stress Scale (Rüsch, Corrigan, Wassel et al., 2009; Rüsch, Corrigan, Powell et al., 2009) measure: Disclosure Distress (Rüsch et al., 2014a) measure: Warwick and Edinburgh Wellbeing Scale (WEMWBS) (Tennant et al 2007) measure: Satisfaction with life (Lehman, 1988) measure: The Questionnaire about the Process of Recovery - 15 (QPR-15) (Niel et al 2007) measure: Internalised Stigma of Mental Illness Inventory (ISMI-10) (Boyd, Otilingam, & Deforge, 2014) measure: Patient Health Questionnaire-4 (PHQ-9) (Kroenke et al 2009) measure: Generalized Anxiety disorder (GAD-7) (Spitzer et al, 2006) measure: Disclosure measure: Feasibility of HOP program measure: Acceptability of HOP program participants measure: Acceptability of HOP peer facilitators sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Nydalen DPS, Division of Mental Health and Addiction, Oslo University Hospital status: RECRUITING city: Oslo zip: 0351 country: Norway name: Mari Husa, MD role: CONTACT phone: 0047 95837846 email: mahusa@ous-hf.no name: Magnus Engen, PhD role: CONTACT phone: 0047 41004660 email: UXENMF@ous.hf.no lat: 59.91273 lon: 10.74609 facility: Søndre Oslo DPS, Division of Mental Health and Addiction, Oslo University Hospital status: NOT_YET_RECRUITING city: Oslo zip: 1281 country: Norway name: Hilde Daler, MSc role: CONTACT phone: 0047 23023100 email: uxruhi@ous-hf.no name: Marit Haram, PhD role: CONTACT phone: 0047 21077000 email: mharam@ous.hf.no lat: 59.91273 lon: 10.74609 hasResults: False
nctId: NCT06384742 id: K23HL157698 type: NIH link: https://reporter.nih.gov/quickSearch/K23HL157698 briefTitle: Shift Worker Intervention for Sleep Health acronym: SWISH overallStatus: NOT_YET_RECRUITING date: 2024-09 date: 2026-09 date: 2027-03 date: 2024-04-25 date: 2024-04-25 name: Oregon State University class: OTHER name: National Heart, Lung, and Blood Institute (NHLBI) briefSummary: The aim of this study is to pilot test a comprehensive, personalized, media-augmented telehealth intervention ("SWISH") designed to improve sleep health among shift workers. conditions: Shift Work Type Circadian Rhythm Sleep Disorder conditions: Insomnia, Psychophysiological studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE maskingDescription: Participants are asked to refrain from mentioning any information about the treatment they receive when interacting with the investigator or outcomes assessors. Participants are asked not to share details of their treatment with other individuals at their workplace. whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 60 type: ESTIMATED name: Shift Worker Intervention for Sleep Health measure: Retention Rate measure: Session Attendance measure: Implementation Assessment Measure measure: Patient Adherence measure: Therapist Fidelity measure: Acceptability of Study Procedures and SWISH measure: Mean 24-hour sleep duration and efficiency measure: Change in Fatigue Severity Scale measure: Change in Epworth Sleepiness Scale measure: Executive functioning measure: PROMIS Sleep Related Impairment measure: PROMIS Sleep Disturbances sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Oregon State University city: Corvallis state: Oregon zip: 97331-1102 country: United States name: Jessee Dietch, PhD role: CONTACT phone: 541-737-1358 email: jessee.dietch@oregonstate.edu name: Jessee Dietch, PhD role: PRINCIPAL_INVESTIGATOR lat: 44.56457 lon: -123.26204 hasResults: False
nctId: NCT06384729 id: 123 briefTitle: Effectiveness of the EXOPULSE Mollii Ⓡ Suit in Patients With Multiple Sclerosis overallStatus: RECRUITING date: 2024-04-01 date: 2024-05-01 date: 2024-09-01 date: 2024-04-25 date: 2024-04-25 name: Universidad Europea de Madrid class: OTHER briefSummary: Abstract:
A randomized, double-blind clinical trial will be conducted, recruiting patients diagnosed with MS , aged 18 or above, with a Functional Ambulation Category (FAC) score between 2 and 4. Patients will be randomly assigned to two groups receiving either inactive or active Exopulse Mollii Ⓡ treatment for 60 minutes, three times a week, for three weeks. Outcome measures include pain, balance, gait speed, risk of falls, perception of walking difficulties, and quality of life assessed using validated scales. Statistical analysis will be performed using SPSS v.29.0.0.0.
This study aims to evaluate the efficacy of the Exopulse Mollii Ⓡ suit in enhancing motor function in MS patients. Findings may contribute to the development of novel therapeutic strategies for managing MS-related symptoms and improving patients' quality of life. conditions: Multiple Sclerosis studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: TREATMENT masking: TRIPLE maskingDescription: A randomized, double-blind clinical trial is proposed, in which two researchers will conduct the intervention, and a third researcher will be responsible for programming the suits and attaching the belt to the suit. The data will be analyzed by a fourth researcher. whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR count: 22 type: ESTIMATED name: EXOPULSE Mollii Ⓡ measure: referred pain measure: Balance measure: gait speed and distance measure: fall risk measure: perception of walking difficulties measure: perceived quality of life sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Cecilia Estrada Barranco status: RECRUITING city: Villaviciosa De Odón state: Madrid zip: 28670 country: Spain name: Cecilia Estrada Barranco, PhD role: CONTACT phone: 686166483 email: cecilia.estrada@universidadeuropea.es lat: 40.35692 lon: -3.90011 hasResults: False
nctId: NCT06384716 id: CEB briefTitle: Evaluation of the Influence of a Core Muscle Control-Based Rehabilitation Program Patients With Multiple Sclerosis overallStatus: RECRUITING date: 2024-02-19 date: 2024-07-01 date: 2024-09-01 date: 2024-04-25 date: 2024-04-25 name: Universidad Europea de Madrid class: OTHER briefSummary: Given the structural relationship of the CORE as a whole, in this study we propose an intervention based on the global motor control of all the structures that make up the CORE to assess its effectiveness on urinary incontinence, sexual dysfunction and balance, as well as its relationship with respiratory function. According to our hypothesis, a global intervention could also be taken into account during conventional treatment in the future, helping to prevent genitourinary dysfunctions derived from alterations in motor control. conditions: Multiple Sclerosis conditions: Pelvic Floor Disorders conditions: Incontinence, Urinary studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: This is a randomised clinical trial. The research will be conducted in accordance with the framework of application of the Helsinki declaration (21) and the law on Personal Data Protection and guarantee of digital rights (Organic Law 3/2018) . The design of this project will follow the definition of the standard elements of a clinical trial protocol: SPIRIT declaration primaryPurpose: TREATMENT masking: SINGLE whoMasked: INVESTIGATOR count: 32 type: ESTIMATED name: rehabilitation programme based on motor control of core muscles measure: Difference in the percentage of initial and final maximum activity of the pelvic floor muscles. measure: - Differences between the initial and final thickness of the oblique abdominis and transverse oblique muscles by ultrasound. measure: - Differences in the assessment of health-related quality of life before and after the intervention measured with the I-QOL questionnaire. measure: - Differences in the assessment of female UI before and after intervention using the I-CIQ questionnaire measure: - Difference in the percentage of initial and final maximum activity of the paravertebral musculature activity. measure: - Differences between initial and final amplitude of initial and final diaphragmatic excursion by ultrasound. measure: - Difference between initial and final FVC/- Differences between the initial and final peak expired volume (FEV1) measure: differences between peak expiratory pressure (PEM) and minimum initial and end inspiratory pressure (MIP). measure: balance sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Cecilia Estrada Barranco status: RECRUITING city: Madrid country: Spain name: Cecilia Estrada-Barranco, PhD role: CONTACT phone: 686166483 email: cecilia.estrada@universidadeuropea.es name: Esther Delgado, PhD role: CONTACT email: esther.delgado@universidadeuropea.es lat: 40.4165 lon: -3.70256 hasResults: False
nctId: NCT06384703 id: 201518015 briefTitle: The Relationship Between Microbiota and Coronary Ectasia overallStatus: COMPLETED date: 2020-11-03 date: 2021-04-25 date: 2021-06-18 date: 2024-04-25 date: 2024-04-25 name: Konya Beyhekim Training and Research Hospital class: OTHER_GOV name: Necmettin Erbakan University briefSummary: Introduction: It is now known that the microbiota is far beyond the microbial communities living in certain parts of our body and functions like a metabolic organ. In addition, the microbiota, through its metabolites, is involved in the pathophysiology or progression of a wide range of diseases, from atherosclerotic diseases to metabolic diseases and even neurological diseases. Among these metabolites, trimethylamine n-oxide metabolite has been shown to be particularly effective on atherosclerotic heart diseases. conditions: Coronary Ectasia conditions: Microbial Disease studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: PROSPECTIVE count: 2 type: ACTUAL name: Taking blood for kit study measure: death sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Necmettin Erbakan University city: Konya zip: 42050 country: Turkey lat: 37.87135 lon: 32.48464 hasResults: False